Provepharm Life Solutions acquires Apollo Pharmaceuticals USA

December 02, 2020

Torys represented Apollo with a team that included Cheryl Reicin, Brook Wong and Matthew Gragtmans (corporate/M&A).

On December 2, 2020, Provepharm Life Solutions S.A. (“Provepharm Life Solutions”) announced the acquisition of Apollo Pharmaceuticals USA Inc. (“Apollo USA”) The business activities of Apollo USA will be merged with those of Provepharm Life Solutions’ American subsidiary located in Pennsylvania.

The financial terms of the deal will not be disclosed.

Further information can be found on Provepharm Life Solutions’ website.

Apollo USA specializes in the commercialization of sterile injectable products for hospital use. It is the U.S. subsidiary of Apollo Pharmaceuticals Inc., which is owned and operated by the Acharya family. The Acharya family also owns and operates SteriMax Inc. one of the largest sterile injectable providers in Canada.

Provepharm Life Solutions is an independent French pharmaceutical company. Since its creation in 1998, the company has leveraged its expertise in fine chemistry and is a pioneer in the ‘third way’, based on the vitalization of mature and known molecules. The first products developed were based on methylene blue and are distributed in over 30 countries around the world. Its strategy consists of developing its range of products, applying its expertise for the vitalization of other molecules and strengthening its international business.